Instituto Nacional de Cancerología
 
Nuestra Misión:
"Desarrollar la atención médica, enseñanza e investigación oncológica de excelencia en México."
 
Idioma/Language/язык/لغة
México 2013

(D:CC) The Best of American Society Clinical Oncology, Cancún 2013

AMC, 2013-05-14 17:17:55.135335
June 28th to 29th, 2013. Fiesta Americana Grand Coral Beach, Cancún, Quintana Roo.

Preliminary Program

 

Friday     June,282013

 

7:00 – 8:30 Breakfast Symposium ROCHE

9:00 – 9:30

Colorrectal Cancer

Speaker: GermánCalderilloM.D. ,National Cancer Institute, Mexico

Miriam Koopman, MD, PhD Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).

John Neil Primrose, MD, FRCS A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.

Alfredo Falcone, MD FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.

COORDINATOR: Consuelo Díaz M.D., National Cancer Institute, Mexico

 

9:30 – 9:50

Colorrectal Cancer

Speaker: Carlos HernándezM.D.,

Christophe Tournigand, MD, PhD Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.

Volker Heinemann, MD Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

COORDINATOR: Consuelo Díaz M.D., National Cancer Institute, Mexico

 

9:50 – 10:20

Gastrointestinal (Noncolorectal) Cancer

Speaker: Erika Ruiz M.D., National Cancer Institute, Mexico

Daniel D. Von Hoff, MD Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates

Akira Fukutomi, MD JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.

Natalie Cook, MD PhDCougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.

J. Randolph Hecht, MD Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

COORDINATOR:Eduardo Téllez M.D., (Puebla)

 

10:20 – 10:40

Gastrointestinal (Noncolorectal) Cancer

Speaker:Jesús López M.D., (Durango)

Kazuhiro Yoshida, MD, PhDSAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer.

Pascal Hammel, MD, PhDComparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

Gary William Middleton, MDA phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

COORDINATOR:Eduardo Téllez M.D., (Puebla)

 

10:40 – 11:00 PANNEL DISCUSSION Q/A

 

11:00 – 11:30 COFFE BREAK

 

11:30 – 12:10

Breast Cancer – HER2/ER

Speaker: SandraSwain M.D.,Washington Hospital Center, Washington

Richard G. Gray, MA, MScaTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Lawrence N. Shulman, MD Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.

G. Thomas Budd, MD S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

COORDINATOR: Claudia Arce M.D.,National Cancer Institute, Mexico

COORDINATOR: Enrique Bargalló M.D., National Cancer Institute, Mexico

 

12:10 – 12:30

Breast Cancer – HER2/ER

Speaker: Vicente Valero M.D., F.A.C.P.,Faculty–M.D. Anderson Cancer Center

Lisa A. Carey, MDClinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.

AmanBuzdar, MD ACOSOG Z1041 (Alliance): Definitive analysis of  randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer.

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Gunter Von Minckwitz A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).

COORDINATOR: Claudia Arce MD., National Cancer Institute, Mexico

COORDINATOR: Enrique Bargalló M.D., National Cancer Institute, Mexico

 

12:30 – 12:50

Breast Cancer – HER2/ER

Speaker:Ricardo Alvarez M.D.,

Fabrice Andre, MD, PhD Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).

Sara A. Hurvitz Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1.

Gabriel N. Hortobagyi, MD, FACP Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.

COORDINATOR: Claudia Arce M.D., National Cancer Institute, Mexico

COORDINATOR: Enrique Bargalló M.D.,  National Cancer Institute, Mexico

 

12:50 – 13:05

Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy

Speaker: Mariana Chávez MacGregor  M.D., MD Anderson

Thomas B. Julian, MD 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.

Emiel J. Rutgers, MD, PhD Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023).

COORDINATOR: Claudia Arce MD., National Cancer Institute, Mexico

COORDINATOR: Enrique Bargalló M.D., National Cancer Institute, Mexico

13:05 – 13:20 PANNEL DISCUSSION Q/A

 

13:20 – 13:35

Gynecologic Cancer

Speaker: Flavia Morales M.D., National Cancer Institute, Mexico

Sandro Pignata, MD, PhD A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)– European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)–Gynecologic Cancer Intergroup (GCIG ) trial.

Andreas Du Bois, MD Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).

COORDINATOR: David Cantú, M.D.,National Cancer Institute, Mexico

                         

13:35 – 13:50

Gynecologic Cancer

Speaker: Dolores Gallardo M.D., National Cancer Institute, Mexico

Sean Kehoe, MD Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: Results from the MRC CHORUS trial.

Jonathan A. Ledermann, BSc MD FRCP Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).

COORDINATOR: David Cantú M.D., National Cancer Institute, Mexico

 

13:50 – 14:00

GynecologicCancer

Speaker:Lucely Cetina M.D., National Cancer Institute, Mexico

KrishnansuSujataTewari, MD Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group.

COORDINATOR: David Cantú M.D., National Cancer Institute, Mexico

 

14:00 – 14:15 PANNEL DISCUSSION Q/A

 

14:15 – 14:25

Head and Neck Cancer

Speaker:Gilberto Morgan M.D., (Guadalajara)

Marcia S. Brose, MD, PhD Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.

David N. Hayes, MD, MPH The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck.

COORDINATOR: Martin Granados M.D., National Cancer Institute, Mexico

14:25 – 14:30 PANNEL DISCUSSION Q/A

 

14:30 – 14:40

Genitourinary (Nonprostate) Cancer

Speaker: Jorge Martínez Cedillo M.D., Instituto Nacional de Cancerología

Robert John Motzer, MD Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).

KarimFizazi, MD A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

AbdenourNabid, MD, FRCP © Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.

COORDINATOR: Miguel A.Jiménez M.D., National Cancer Institute, Mexico

COORDINATOR: Miguel A.Álvarez M.D., National Cancer Institute, Mexico

 

14:40 – 14:50

Genitourinary (Prostate) Cancer

Speaker: Abraham Ruiz M.D.,National Cancer Institute, Mexico

Michael K. Brawer, MD Prolaris: A novel genetic test forprostatecancer prognosis.

Dana E. Rathkopf, MD Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

COORDINATOR: Miguel A. Jiménez M.D., National Cancer Institute, Mexico

COORDINATOR: Miguel A .Álvarez M.D., National Cancer Institute, Mexico

 

14:50 – 15:00 PANNEL DISCUSSION Q/A

 

15:00 – 16:30 Lunch Symposium  (Astra Zeneca)

 

Saturday June,292013

 

8:00 – 9:30 Breakfast Symposium ROCHE

 

9:30 – 9:50

Melanoma

Speaker: Charles M. Balch, M.D., F.A.C.S., Johns Hopkins Institute, Baltimore

Richard D. Carvajal, MD Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

F. Stephen Hodi, MD Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.

Omid Hamid, MD Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).(2 of 3)

COORDINATOR: Héctor MartínezM.D., National Cancer Institute, Mexico

 

9:50 – 10:10

Melanoma

Speaker:Jose Luis Aguilar M.D., Instituto Nacional de Cancerología

AntoniRibas, MD Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. (1 of 3)

Jeffrey S. Weber Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab. (3 of 3)

COORDINATOR: Héctor MartínezM.D., National Cancer Institute, Mexico

 

10:10 – 10:20

Melanoma

Speaker:Jose Francisco Alexander M.D., (Guadalajara)

Jedd D. Wolchok, MD, PhD Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

Robert Hans IngemarAndtbacka, MD OPTiM: A randomized phase III trial of talimogenelaherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

COORDINATOR: Héctor MartínezM.D., National Cancer Institute, Mexico

10:20 – 10:30 PANNEL DISCUSSION Q/A

 

10:30 – 11:00

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Speaker:Chandra Bellani M.D., Penn State Hershey Cancer Institute, Pennsylvania

Charles Andrew Butts, MD, FRCPC START: A phase III study of L-BLP25 (tecemotide) cancer immunotherapy for unresectable stage III non-small cell lung cancer.

Jeffrey D Bradley, MD A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.

MiklosPless, MD Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).

Neal Ready, MD, PhD Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small cell lung cancer: A randomized, placebo controlled phase II study CALGB 30504 (ALLIANCE).

Suresh S. Ramalingam, MD A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

COORDINATOR: Jaime de la Garza M.D.,National Cancer Institute, Mexico

COORDINATOR: Juan Francisco GonzálezM.D., Hospital Universitario

 

11:00 – 11:10

Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers

Speaker:Omar Macedo M.D., National Cancer Institute, Mexico

David R. Spigel, MD Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Alice Tsang Shaw, MD, PhDClinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

COORDINATOR: Jaime de la Garza M.D.,National Cancer Institute, Mexico

COORDINATOR: Juan Francisco González Guerrero M.D.,

 

11:10 – 11:25

Lung Cancer - Non-small Cell Metastatic

Speaker:Oscar G. Arrieta M.D., National Cancer Institute, Mexico

Ralph Zinner, MD Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).

Chiara Lazzari Randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

Martin Reck Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: Results of Lume-Lung 1, a randomized, double-blind, phase III trial.

COORDINATOR: Jaime de la Garza M.D., National Cancer Institute, Mexico

COORDINATOR: Juan Francisco González Guerrero M.D.,

 

11:25 – 11:40 PANNEL DISCUSSION Q/A

 

11:40 – 12:10 COFFE BREAK

 

12:10 – 12:20

Central Nervous System Tumors

Speaker: To be confirmed

Mark R. Gilbert RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

Walter TaalA randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.

Terri S. Armstrong, PhD, ANP-BC, FAANP Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825.

COORDINATOR: BernardoCacho M.D., National Cancer Institute, Mexico

COORDINATOR: Jorge Luis Martínez M.D., National Cancer Institute, México

 

12:20 – 12:30

Central Nervous System Tumors

Speaker:Christian A. Flores M.D., National Cancer Institute, Mexico

Stephen R. Rapp, Ph.D.Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors.

Ulrich Herrlinger Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

COORDINATOR: Cacho M.D., National Cancer Institute, Mexico

 

12:30 – 12:40 PANNEL DISCUSSION Q/A

 

13:00 – 15:00 Lunch Symposium BOA- HOC (Takeda)

Leukemia, Myelodysplasia, and Transplantation

Speaker:  

Michael W. N. Deininger, MD, PhD Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.

Andrea Toma A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.

ValentinGoede Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.

Susan Mary O'Brien, MD A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Lymphoma and Plasma Cell

John Leonard, MD Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study.

Carrie A. ThompsonUtility of post-therapy surveillance scans in DLBCL.

Mario Boccadoro, MD Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.

Jesus San Miguel, MD, PhD MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).

COORDINATOR: Myrna Candelaria M.D., Nacional Cancer Institute, Mexico

 

 

 

 

Av. San Fernando No. 22, Col. Sección XVI Delegación Tlalpan, C.P. 14080 México, D.F. Tel.: 5628-0400 Sitio creado por la Dirección de Docencia, México 2013. Todos los derechos reservados.Políticas de Privacidad